跳至主要内容
临床试验/NCT02976051
NCT02976051Unknown2 期

DAHANCA 33: Functional Image Guided Dose-escalated Radiotherapy to Patients With Hypoxic Squamous Cell Carcinoma of the Head and Neck

Danish Head and Neck Cancer Group2 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2017年1月最近更新:
适应症

试验速览

阶段
2 期
入组人数
60
试验地点
2
主要终点
Loco-regional failure

研究概览

简要总结

Aim: To improve curability of radiotherapy in HNSCC patients identified by hypoxic FAZA-PET scanning

详细描述

Prospective phase II study aiming to improve the outcome in hypoxic resistent patients identified by FAZA-PET.

Inclusion:

Patients must fulfill the following:

Positive hypoxic FAZA-PET Scanning (as described in DAHANCA 24 - see citation) Stage III-IV, Squamous cell carcinoma of the larynx, pharynx or oral cavity (HPVneg (oropharynx) Indication for hyperfractionated accelerated radiotherapy with concommitant cis-platin and nimorazole

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Stage III-IV larynx, pharynx, oral cavity
  • Hypoxic FAZA-PET positive
  • Indication for primary radio-chemotherapy
  • Informed consent

排除标准

  • HPV positive oropharynx cancer
  • Primary surgery

结局指标

主要结局

Loco-regional failure

时间窗: Year 3

loco-regional failure defined as persistent or recurrent disease in tumor and/or regional lymphnode sites (within the radiotherapy treated volume). The primary endpoint did not include the effect of a successful procedure with salvage surgery (no primary neck dissection was allowed).

次要结局

  • Acute radiation related morbidity(Month 3)
  • Overall survival(Year 3)
  • Late radiation related morbidity(Year 3)
  • Disease-specific death(Year 3)

研究者

申办方类型
Network
责任方
Principal Investigator
主要研究者

Jens Overgaard

Professor, MD DMSc

Danish Head and Neck Cancer Group

研究点 (2)

Loading locations...

相似试验